CytoDyn (CYDY) EBT Margin (2021 - 2022)
CytoDyn (CYDY) posted EBT Margin of 247414.71% for Q2 2022, down 1289.03% on a QoQ basis from 17812.0% in Q4 2021.
CytoDyn (CYDY) EBT Margin (2021 - 2022) Analysis & Trends
CytoDyn's EBT Margin history runs 2 years deep, the most recent figure standing at 247414.71% for Q2 2022.
- Quarterly EBT Margin changed N/A year-over-year to 247414.71% in Q2 2022, while the trailing twelve-month figure through May 2022 was 70273.33% (changed N/A YoY) and the FY2022 annual result came in at 70273.33%, changed N/A from the prior year.
- EBT Margin was 247414.71% for Q2 2022 at CytoDyn, down from 17812.0% in the prior quarter.
- Across five years, EBT Margin topped out at 17812.0% in Q4 2021 and bottomed at 247414.71% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytoDyn | 267.79 Mn | 267.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | -247,414.71% |
| Nov 30, 2021 | -17,812.00% |
| Aug 31, 2021 | -110,578.05% |